Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.

about

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.

Item

http://www.wikidata.org/entity/Q55354383

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Binimetinib (MEK162) in recurr ...... herapy and hormonal treatment.

@en

Binimetinib

@nl

type

Item

label

Binimetinib (MEK162) in recurr ...... herapy and hormonal treatment.

@en

Binimetinib

@nl

prefLabel

Binimetinib (MEK162) in recurr ...... herapy and hormonal treatment.

@en

Binimetinib

@nl

P1476

Binimetinib (MEK162) in recurr ...... herapy and hormonal treatment.

@en

P2093

Alessandro D Santin

http://www.w3.org/2001/XMLSchema#string

Chanhee Han

http://www.w3.org/2001/XMLSchema#string

Luca Zammataro

http://www.w3.org/2001/XMLSchema#string

Peter E Schwartz

http://www.w3.org/2001/XMLSchema#string

Stefania Bellone

http://www.w3.org/2001/XMLSchema#string

P2860

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

MEK1/2 inhibitors in the treatment of gynecologic malignancies.

Low-grade epithelial ovarian cancer: a number of distinct clinical entities?

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

P304

41-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.GORE.2018.05.011

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29946554

http://www.w3.org/2001/XMLSchema#string

P932

6014583

http://www.w3.org/2001/XMLSchema#string